Medbank
MEDBANK specializes in genetic analysis utilizing next generation sequencing.
Our focus is on genetic testing using whole genome analysis. The term “MEDBANK” is also used to describe the fact that today, people deposit money in banks, but we believe that the time will come in the near future when genome information will be deposited in banks. We want to be that bank. That’s why we have named our company MEDBANK.
The era of personalized medicine, in which prevention and treatment are based on our genome information, which will never change, is coming with AI. We will create an era in which AI will analyze information from whole genome analysis and not only predict the risk of disease onset, but also optimize treatment and assess the risk of serious illness based on genetic information.
As a new challenge for MEDBANK, we have also introduced the next-generation sequencer (NGS) AVITI. The challenges of genome analysis were cost and slow turnaround time. In fact, many researchers have closed the door to genome analysis research due to limited research funding. In addition, the 1-2 month turnaround time for analysis has caused delays in research. MEDBANK provides genome analysis at a low cost and with a fast turnaround time. In addition, AVITI performs very high-quality analysis compared to conventional NGS. We will utilize AVITI to promote genome research in Asia and Oceania region, especially in Singapore.